Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.74 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.74 |
| ▸ | ITGAV | P06756 | 15/20 | 0.72 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.71 |
| ▸ | ITGA5 | P08648 | 6/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366713 | 1.00 | ITGB3 (0.74) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL31294830 | 0.95 | ITGB3 (0.80) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL29992576 | 0.95 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL20917265 | 0.95 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL29686672 | 0.93 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL29464836 | 0.92 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL29578997 | 0.92 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL30098352 | 0.89 | ITGB3 (0.76) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL31614099 | 0.89 | ITGB3 (0.69) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL30467217 | 0.89 | ITGB3 (0.69) | ITGB3ITGA2BITGAVITGB5ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12146869-B2 | Methods and compositions for analyte quantification | MATTERWORKS INC (US) | 2024-11-19 | — | — | US | claimed |
| EP-4355793-B1 | THERMORESPONSIVE HYDROGELS AS MICRONICHES FOR THE GROWTH AND CONTROLLED RELEASE OF PLURIPOTENT STEM CELLS AND PREPARATION METHOD THEREOF | UNIV BERLIN FREIE (DE) | 2024-10-30 | — | — | EP | claimed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | claimed |
| US-20240279405-A1 | THERMORESPONSIVE HYDROGELS AS MICRONICHES FOR THE GROWTH AND CONTROLLED RELEASE OF PLURIPOTENT STEM CELLS AND PREPARATION METHOD THEREOF | FREIE UNIVERSITÄT BERLIN (DE) | 2024-08-22 | — | — | US | claimed |
| CN-118497109-A | Method for maintaining and improving stem cell multipotency based on integrin antagonists or inhibitors | 东北大学 | 2024-08-16 | — | — | CN | claimed |
| US-20240167986-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2024-05-23 | — | — | US | claimed |
| EP-4355793-A1 | THERMORESPONSIVE HYDROGELS AS MICRONICHES FOR THE GROWTH AND CONTROLLED RELEASE OF PLURIPOTENT STEM CELLS AND PREPARATION METHOD THEREOF | Freie Universität Berlin (DE) | 2024-04-24 | — | — | EP | claimed |
| US-20230137741-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2023-05-04 | — | — | US | claimed |
| WO-2023077166-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2022263560-A1 | THERMORESPONSIVE HYDROGELS AS MICRONICHES FOR THE GROWTH AND CONTROLLED RELEASE OF PLURIPOTENT STEM CELLS AND PREPARATION METHOD THEREOF | FREIE UNIVERSITÄT BERLIN (DE) | 2022-12-22 | — | — | WO | claimed |
| EP-4105245-A1 | THERMORESPONSIVE HYDROGELS AS MICRONICHES FOR THE GROWTH AND CONTROLLED RELEASE OF PLURIPOTENT STEM CELLS AND PREPARATION METHOD THEREOF | Freie Universität Berlin (DE) | 2022-12-21 | — | — | EP | claimed |
| CN-122057032-A | Therapeutic application of targeted exosomes in improving acute ischemic stroke blood brain barrier damage | 北京清华长庚医院 | 2026-05-19 | — | — | CN | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12584112-B2 | Organoid tissue engineering | Ecolepol Ytechnique Federale de Lausanne (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3718570-A1 | PHTHALOCYANINE PROBES AND USES THEREOF | LI-COR, INC. (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200179514-A1 | PHTHALOCYANINE PROBES AND USES THEREOF | LI-COR, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3148583-B1 | PHTHALOCYANINE PROBES AND USES THEREOF | LI COR INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10588972-B2 | Phthalocyanine probes and uses thereof | LI-COR, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20150374819-A1 | PHTHALOCYANINE PROBES AND USES THEREOF | LI-COR, INC. (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584112-B2 | Organoid tissue engineering | KIT, EPCAM, ALPG | ITGB3 19/4885ITGA2B 65/4885ITGAV 313/4885 |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CMKLR2, CRKL, CMKLR1 | ITGB3 132/4885ITGA2B 94/4885ITGAV 26/4885 |
| US-20150374819-A1 | PHTHALOCYANINE PROBES AND USES THEREOF | CD47, PHLPP1, PHLPP2 | ITGB3 1734/4885ITGA2B 1199/4885ITGAV 1591/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ITGB3 1125/4885ITGA2B 1286/4885ITGAV 1364/4885 |
| US-10588972-B2 | Phthalocyanine probes and uses thereof | CD47, PHLPP1, PHLPP2 | ITGB3 1734/4885ITGA2B 1199/4885ITGAV 1591/4885 |
| US-20200179514-A1 | PHTHALOCYANINE PROBES AND USES THEREOF | CD47, PHLPP1, PHLPP2 | ITGB3 1734/4885ITGA2B 1199/4885ITGAV 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.